Lucid Diagnostics Inc
NASDAQ:LUCD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Linc AB
STO:LINC
|
SE |
|
Cutera Inc
NASDAQ:CUTR
|
US |
|
Hannover Rueck SE
XETRA:HNR1
|
DE |
|
SingSong Holdings Co Ltd
KRX:006880
|
KR |
|
agilon health inc
NYSE:AGL
|
US |
Lucid Diagnostics Inc
Research & Development
Lucid Diagnostics Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
L
|
Lucid Diagnostics Inc
NASDAQ:LUCD
|
Research & Development
-$6m
|
CAGR 3-Years
14%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Research & Development
-$2.1B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-9%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Research & Development
-$1.1B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-11%
|
|
|
Stryker Corp
NYSE:SYK
|
Research & Development
-$1.6B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-10%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Research & Development
-$2.9B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-8%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Research & Development
-$1.3B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-21%
|
|
Lucid Diagnostics Inc
Glance View
Lucid Diagnostics, Inc. develops medical testing devices. The company is headquartered in New York City, New York. The company went IPO on 2021-10-14. The firm is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or reflux, that leads to esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). Its products include EsoCheck and EsoGuard. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in an office procedure. The company consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. EsoGuard is a bisulfite-converted next generation sequencing (NGS) deoxyribonucleic acid (DNA) assay performed on surface esophageal cells collected with EsoCheck. The firm is a subsidiary of PAVmed Inc.
See Also
What is Lucid Diagnostics Inc's Research & Development?
Research & Development
-6m
USD
Based on the financial report for Dec 31, 2024, Lucid Diagnostics Inc's Research & Development amounts to -6m USD.
What is Lucid Diagnostics Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-12%
Over the last year, the Research & Development growth was 17%. The average annual Research & Development growth rates for Lucid Diagnostics Inc have been 14% over the past three years , -12% over the past five years .
